Compare Global X Lithium & Battery Tech ETF (LIT) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Lithium & Battery Tech ETF vs Summit Therapeutics Inc — how do they compare? Global X Lithium & Battery Tech ETF trades at $75.25, while Summit Therapeutics Inc trades at $15.06 (market cap $12.06B). The key difference: Global X Lithium & Battery Tech ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| LIT | SMMT | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $91.62 | $26.98 |
52-Week Low | $44.96 | $12.55 |
Market Cap | — | $12.06B |
Enterprise Value | — | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LIT trades at $75.21, up 0.63% with a bullish technical signal supported by moving averages. The stock has doubled over the past year, driven by strong momentum in energy storage, semiconductors, and electric vehicles. Recent news highlights global EV sales growth and China's ambitious 30% NEV fleet target by 2030, providing positive sector tailwinds. However, key financial ratios remain undisclosed in current data.
The outlook remains positive given sector catalysts in EVs and energy storage, though RSI levels suggest potential near-term overbought conditions. Investment opportunities center on lithium market inflection and semiconductor demand, while risks include competitive pressures and reliance on Chinese EV policy developments. The stock's 125% return from last year's low indicates strong momentum but warrants caution at current levels.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X Lithium & Battery Tech ETF
LIT invests in the full lithium cycle, from mining and refining to battery production and EV manufacturing. It tracks the Solactive Global Lithium Index, with top holdings including Rio Tinto, Albemarle, and Tesla, as well as major battery makers like Samsung SDI.
Read more on LIT →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
